$522 Million is the total value of Flagship Pioneering Inc.'s 7 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 25.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EVLO | New | EVELO BIOSCIENCES INC | $215,154,000 | – | 18,233,403 | +100.0% | 41.21% | – |
DNLI | DENALI THERAPEUTICS INC | $136,011,000 | -22.5% | 8,918,749 | 0.0% | 26.05% | -48.8% | |
MCRB | SERES THERAPEUTICS INC | $109,073,000 | +17.2% | 12,682,876 | 0.0% | 20.89% | -22.6% | |
SYRS | SYROS PHARMACEUTICALS INC | $32,717,000 | -21.3% | 3,204,437 | 0.0% | 6.27% | -48.0% | |
QTRX | QUANTERIX CORP | $29,158,000 | -15.7% | 2,030,495 | 0.0% | 5.58% | -44.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-07
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
MODERNA INC | 20 | Q3 2023 | 76.9% |
EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
Axcella Health Inc | 17 | Q2 2023 | 3.5% |
KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
13F-HR | 2023-11-14 |
4 | 2023-09-15 |
4 | 2023-08-15 |
13F-HR | 2023-08-14 |
4 | 2023-07-13 |
13F-HR | 2023-05-15 |
4 | 2023-02-27 |
13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.